ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,675.12
0.64%
Dow Jones
41,841.63
0.85%
US Dollar vs MXN
19.98203
0.11%
Brent Oil
71.005
0.49%
Bitcoin
83,145.44
-1.09%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Acumen Pharmaceuticals Inc (ABOS)

  7. Acumen Pharmaceuticals Inc (ABOS) Noticias

ABOS

Acumen Pharmaceuticals (ABOS)

Acumen Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ABOS
FechaHoraFuenteTítuloSímboloCompañía
12/03/202507:00GlobeNewswire Inc.Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual MeetingNASDAQ:ABOSAcumen Pharmaceuticals Inc
10/03/202515:00GlobeNewswire Inc.Acumen Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:ABOSAcumen Pharmaceuticals Inc
23/01/202520:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
23/01/202515:17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
09/01/202507:00GlobeNewswire Inc.Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety FindingsNASDAQ:ABOSAcumen Pharmaceuticals Inc
26/11/202415:00GlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
12/11/202415:29Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ABOSAcumen Pharmaceuticals Inc
12/11/202406:00GlobeNewswire Inc.Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business HighlightsNASDAQ:ABOSAcumen Pharmaceuticals Inc
11/11/202415:00GlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the Stifel Healthcare ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
06/11/202416:24Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
06/11/202415:00GlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the UBS Global Healthcare ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
06/11/202407:00GlobeNewswire Inc.Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of QualityNASDAQ:ABOSAcumen Pharmaceuticals Inc
05/11/202415:00GlobeNewswire Inc.Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024NASDAQ:ABOSAcumen Pharmaceuticals Inc
31/10/202407:05GlobeNewswire Inc.Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
23/10/202407:00GlobeNewswire Inc.Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
30/09/202415:00GlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
26/09/202407:00GlobeNewswire Inc.Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s DiseaseNASDAQ:ABOSAcumen Pharmaceuticals Inc
25/09/202415:00GlobeNewswire Inc.Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024NASDAQ:ABOSAcumen Pharmaceuticals Inc
03/09/202415:00GlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
13/08/202406:48Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABOSAcumen Pharmaceuticals Inc
13/08/202406:00GlobeNewswire Inc.Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business HighlightsNASDAQ:ABOSAcumen Pharmaceuticals Inc
06/08/202415:00GlobeNewswire Inc.Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024NASDAQ:ABOSAcumen Pharmaceuticals Inc
29/07/202406:00GlobeNewswire Inc.Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s DiseaseNASDAQ:ABOSAcumen Pharmaceuticals Inc
28/07/202406:30GlobeNewswire Inc.Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024NASDAQ:ABOSAcumen Pharmaceuticals Inc
14/05/202406:00GlobeNewswire Inc.Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:ABOSAcumen Pharmaceuticals Inc
13/05/202415:00GlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
08/05/202416:47GlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
08/05/202407:00GlobeNewswire Inc.Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s DiseaseNASDAQ:ABOSAcumen Pharmaceuticals Inc
07/05/202415:00GlobeNewswire Inc.Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024NASDAQ:ABOSAcumen Pharmaceuticals Inc
16/04/202407:00GlobeNewswire Inc.Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual MeetingNASDAQ:ABOSAcumen Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ABOS

Su Consulta Reciente

LATK
BRISEUSDT
Bitgert
LSE
AGL
Angle
LATK
METETH
Metronome
LSE
0KJF
Apranga Apb
NYSE
CFXA
Colfax
USOTC
BLGO
BioLargo (QX)
TSX
BABY
Else Nutrition
NASDAQ
ABMCYXX
Jpmorgan Chase Financial...
LSE
HAWK
Nighthawk Energy
NASDAQ
CAKMX
Canoe Global Income Fund...
TSXV
GRZ
Gold Reserve
COIN
MTHDUSD
Method
BOV
XRXB34Q
Xerox
COIN
OTXUSD
Octanox
BIT
UC92AJ
Unicredit Bank
COIN
KOLUSD
Kollect
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios